8 Hikma PHarmaceuticals Plc annual report 2011 GROu p at a Gl a nC E WHat WE dO & WHERE WE dEVElOp, manufaCtuRE and maRkEt GEnERIC pHaRmaCEutICal pROduCts WItHIn tHREE CORE BusInEssEs.
WE aRE alsO a lEadInG lICEnsInG paRtnER In tHE mEna REGIOn.
OuR OpERatIOns span OVER 45 COuntRIEs and fOCus On a BROad RanGE Of tHERapEutIC aREas thirteenth largest generics company Qua l I t y f OR l I f E inthe us market focus on quality manufacturing andhigh service levels GEnERICs strong emphasis on niche products, including controlled substances selliNG oral GeNeric leveraging our efficient and lower Products across tHe us cost manufacturing facilities in meNa 50 products in 122 dosage forms andstrengths 2011 reveNue GeoGraPHical area: us $154.8m toP Products: 11.3 amoxicillin % doxycycline Gemfibrozil Isosorbide mononitrate More information see page 26 prednisone GrouP overview 9 Hikma PHarmaceuticals Plc annual report 2011 leading global manufacturer of Qua l I t y f OR l I f E quality sterileinjectables us fda approved manufacturing facilities in the us, Portugal and InjECtaBlEs Germany range of manufacturing capabilities selliNG sPecialised iNJectaBle including sterile liquid, powder, Products GloBally lyophilised and cytotoxic products Broad product portfolio including cNs, anti-infective, cardiovascular and oncology products 2011 reveNue 169 products in 308 dosage forms and strengths GeoGraPHical area: $315.7m us, Europe, mEna 100.5% toP Products: Cefizox Cefazolin Ciprolon fentanyle citrate More information see page 22 Ondanestron fifth largest pharmaceutical company in the meNa region Qua l I t y f OR l I f E 40% of Branded sales from in-licensed products BRandEd 1,649 reps targeting physicians and pharmacists across the region selliNG BraNded GeNerics strong anti-infective franchise and aNd iN-liceNsed Products increasing focus on cardiovascular, across tHe meNa reGioN diabetes and cNs products leading markets are algeria, egypt, Jordan and saudi arabia 448 products in 1,168 dosage forms 2011 reveNue and strengths GeoGraPHical area: $441.9m mEna 12.1% toP Products: actos amoclan kEy: Blopress prograf 22 manufaCtuRInG plants 5 R&d CEntREs More information see page 18 suprax 10 Hikma PHarmaceuticals Plc annual report 2011
